Cannabis in Adults with Cancer
Key Points
Key Points
- Cannabis and/or cannabinoid access and use by adults with cancer has outpaced the science supporting their clinical use.
- This guideline provides strategies for open, nonjudgmental communication between adults with cancer and clinicians about the use of cannabis and cannabinoids.
- Clinicians should recommend against using cannabis or cannabinoids as a cancer-directed treatment unless within the context of a clinical trial.
- Cannabis and/or cannabinoids may improve refractory, chemotherapy-induced nausea and vomiting (CINV) when added to guideline-concordant antiemetic regimens.
- Whether cannabis and/or cannabinoids can improve other supportive care outcomes remains uncertain.
Treatment
Treatm...
...inical Communication and...
...on 1.1Health systems and clinicians,...
...ion 1.2Given the high prevalence of cannabis a...
...dation 1.3When adults with cancer use cannabis an...
...r Treatment...
...mendation 2.1Clinicians should recommen...
...ecommendation 2.2Clinicians should recommen...
...ent-related Toxicity, Symptoms, and Qua...
...endation 3.1...
...and nabilone] (EB, , M, Weak)3499376...
...BD extract] (EB, , L, Weak)349937...
...ion 3.2Outside of a clinical trial, clinicians sh...
...commendation 3.3Evidence remains insu...
...Taking an In-depth History of Cannabis and/o...
...ble 2. Summary of Recommendations Pertaini...
...l Safety AwarenessHaving trouble viewin...
...e 1. Endocannabinoid Syste...
...ieves that cancer clinical trials are vit...